Page 46 - Read Online

Page 14 of 14 Moriguchi et al. Hepatoma Res 2019;5:43 I http://dx.doi.org/10.20517/2394-5079.2019.20

122. Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic
review and meta-analysis. J Clin Endocrinol Metab 2012;97:2347-53.
123. Zheng L, Yang W, Wu F, Wang C, Yu L, et al. Prognostic significance of AMPK activation and therapeutic effects of metformin in
hepatocellular carcinoma. Clin Cancer Res 2013;19:5372-80.
124. Aljada A, Mousa SA. Metformin and neoplasia: implications and indications. Pharmacol Ther 2012;133:108-15.
125. Zhang X, Harmsen WS, Mettler TA, Kim WR, Roberts RO, et al. Continuation of metformin use after a diagnosis of cirrhosis
significantly improves survival of patients with diabetes. Hepatology 2014;60:2008-16.
126. Chen TM, Lin CC, Huang PT, Wen CF. Metformin associated with lower mortality in diabetic patients with early stage hepatocellular
carcinoma after radiofrequency ablation. J Gastroenterol Hepatol 2011;26:858-65.
127. Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk
of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol 2013;24:2449-55.
128. Donadon V, Balbi M, Ghersetti M, Grazioli S, Perciaccante A, et al. Antidiabetic therapy and increased risk of hepatocellular
carcinoma in chronic liver disease. World J Gastroenterol 2009;15:2506-11.